Tirzepatide

Overview

Tirzepatide is a synthetic 39-residue peptide that agonises two incretin receptors: the GLP-1 receptor and the GIP receptor. It is the first dual incretin agonist to be characterised at scale, and its research record includes a direct head-to-head comparison against semaglutide — unusual in a field where compounds are typically compared only against placebo.

The interesting part of its design is not that it hits two receptors. It is which two, and which one it is built from.

Chemical identity

• Also known as: LY3298176
• CAS number: 2023788-19-2
• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: 4813.53 g/mol
• Classification: Dual GIP and GLP-1 receptor agonist, acylated peptide
• Length: 39 residues plus the acylation chain
• Appearance: White lyophilised powder

At 4,814 g/mol this is one of the larger molecules in the catalogue and well beyond the size where a structural depiction remains readable. As with semaglutide, the formula contains no sulfur — no cysteine, no methionine — which simplifies its stability profile.

Two incretins, not one

The incretin effect — the observation that glucose taken orally produces a far larger insulin response than the same glucose given intravenously — is mediated by two hormones, not one.

GLP-1 is the familiar one. GIP, glucose-dependent insulinotropic polypeptide, is the other, and it was actually discovered first. It is released from the upper small intestine after eating and, like GLP-1, stimulates insulin secretion in a glucose-dependent way.

GIP spent decades being regarded as the less interesting of the pair. Its insulinotropic effect appears blunted in type 2 diabetes, which led to a reasonable conclusion that targeting it would be unproductive — why agonise a receptor whose response is already impaired? Pharmaceutical attention concentrated almost entirely on GLP-1 as a result.

Tirzepatide is interesting largely because that conclusion turned out to be wrong, or at least incomplete. Combined GIP and GLP-1 agonism produced effects exceeding what GLP-1 agonism alone achieves, which has reopened GIP biology as an active research question rather than a closed one.

Built on the other backbone

A detail that is frequently stated backwards: tirzepatide is not a GLP-1 analogue that also happens to hit GIP. Its sequence is based on the GIP peptide, engineered to acquire GLP-1 receptor activity it would not otherwise have.

That direction of travel matters when reading the literature. Comparisons framed as “a GLP-1 drug with something added” misdescribe the molecule; it is closer to a GIP agonist taught to do a second job.

The engineering follows a pattern that will be familiar from other compounds here:

• Non-standard amino acids at two positions, including position 2, which is where DPP-4 would otherwise cleave the peptide. The same problem, and broadly the same solution, as semaglutide’s Aib substitution.
• Acylation with a C20 fatty diacid on a lysine side chain, giving reversible albumin binding and a half-life around five days — the same reversible strategy used by semaglutide and cagrilintide, rather than the covalent approach of CJC-1295 with DAC.
• Sequence changes conferring GLP-1 receptor affinity, which is the genuinely novel part — retaining full activity at the parent receptor while acquiring meaningful activity at a related but distinct one.

Imbalanced agonism

Tirzepatide is not equally potent at its two targets. Published characterisation describes it as substantially more potent at the GIP receptor than at the GLP-1 receptor — the compound is described in the literature as an imbalanced or biased dual agonist.

Whether that imbalance is optimal is an open research question and one of the more interesting aspects of the compound. It is not obviously a compromise: the ratio is a design parameter, and other dual agonists with different ratios exist precisely to explore what the ratio does. For anyone studying incretin pharmacology, tirzepatide is a specific point in that design space rather than a generic dual agonist.

How it compares with semaglutide

These two compounds have been compared directly in a randomised trial, which makes the comparison unusually well grounded.

• Receptor targets: tirzepatide, GIP and GLP-1; semaglutide, GLP-1 alone.
• Parent hormone: tirzepatide is built from GIP; semaglutide from GLP-1.
• Half-life: approximately five days against approximately one week.
• Albumin strategy: both use reversible fatty acid binding rather than covalent conjugation.
• Size: 4,814 against 4,114 g/mol — tirzepatide is the larger peptide, at 39 residues against 31.

The head-to-head trial reported by Frías and colleagues is worth reading directly rather than through summaries, since it is one of the few places in this catalogue where two compounds have been compared under controlled conditions rather than inferred from separate studies.

Research record

• Discovery and pharmacology. Coskun and colleagues published the characterisation of the molecule, including its receptor pharmacology and the rationale for dual agonism.
• Head-to-head comparison. A randomised trial compared tirzepatide against semaglutide in type 2 diabetes.
• Body weight. A separate randomised programme examined effects on body weight in populations with obesity.

Reported observations

The adverse effects most consistently reported are gastrointestinal — nausea, diarrhoea, vomiting, constipation — dose-related and most pronounced during escalation, the pattern familiar from incretin compounds generally. The trial literature also documents gallbladder-related events and pancreatitis at lower frequency, and carries warnings derived from rodent studies regarding thyroid C-cell tumours.

As with semaglutide, these come from large controlled trials with systematic adverse event collection rather than from small preclinical studies, which makes them substantially more reliable than equivalent statements about most compounds in this catalogue.

Regulatory status

Tirzepatide is an approved prescription medicine in the United States, the European Union and other jurisdictions, marketed under brand names for type 2 diabetes and for weight management.

The same two points apply as for semaglutide. Material supplied for laboratory research is not a pharmaceutical product — it has not been manufactured, tested or released under the controls governing an approved medicine, and it is not a substitute for one. And the clinical properties documented in the trial literature were established with the approved product; nothing here should be read as suggesting research material carries them.

Anyone whose interest is medical rather than experimental should be speaking to a clinician.

Handling, reconstitution and storage

• Lyophilised storage: sealed, refrigerated, protected from light. Freeze for long-term storage.
• No oxidation-prone residues. No sulfur in the formula means no methionine and no cysteine, removing the most common chemical degradation route.
• Surface activity from the acylation. The fatty acid chain that binds albumin also promotes adsorption onto container walls and foaming on agitation. Do not shake.
• Reconstitution: add diluent slowly down the vial wall, allow to dissolve undisturbed.
• After reconstitution: refrigerate, protect from light, minimise freeze–thaw cycles.
• Concentration: our peptide reconstitution calculator converts vial quantity, diluent volume and syringe size into concentration per unit.

Purity and analytical verification

Thirty-nine residues, two non-standard amino acids and a site-specific acylation make this among the more demanding syntheses represented here, and the analytical requirements follow from that complexity.

Mass confirmation is the key check, for the same reason as semaglutide: a batch in which acylation failed is missing a large, well-defined mass, and an unacylated backbone would be pharmacologically different in kind — a peptide lasting minutes rather than days. Comparing the measured mass against the expected 4,814 g/mol establishes that the acylation is present. Noting merely that “a peptide” was detected does not.

HPLC purity quantifies deletion sequences, of which a 39-step synthesis generates many, along with impurities arising from the acylation chemistry itself.

We publish third-party certificates of analysis by batch.

References

• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 2018. PMID 30473097
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 2021. PMID 34170647
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022. PMID 35658024

Summary

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist, CAS 2023788-19-2, molecular formula C₂₂₅H₃₄₈N₄₈O₆₈, molecular weight 4,813.53 g/mol. Its 39-residue sequence is built on a GIP backbone engineered to acquire GLP-1 receptor activity, not the reverse, and it is more potent at GIP than at GLP-1 — an imbalance treated in the literature as a design parameter rather than a limitation. Non-standard amino acids block DPP-4 cleavage and a C20 fatty diacid gives reversible albumin binding and a half-life of about five days. It is an approved prescription medicine, and its most useful research feature is a direct randomised comparison against semaglutide.

For laboratory research use only. Not for human consumption. This material is not a drug, food, or cosmetic and may not be sold or used for any purpose other than in vitro or non-human laboratory research. References to clinical studies describe the published scientific literature and are not guidance for use.